Participated · Equity · Jul 2026

Mentari’s lead programs are MT-001, an anti-PACAP monoclonal antibody slated for first-in-human regulatory filings in mid-2026, and MT-002, an anti-CGRP x PACAP bispecific antibody expected to enter regulatory filings in the first quarter of 2027. The programs were discovered by Paragon Therapeutics and have shown strong in vitro potency and favorable pharmacokinetic profiles in preclinical studies. The therapies are designed to target complementary migraine pathways and address patients who experience limited benefit from currently approved anti-CGRP treatments. Mentari announced a $290 million private placement that it says will fund operations through 2028 and entered an all-stock merger agreement with InMed Pharmaceuticals to gain public market infrastructure. Following the transaction the combined company is expected to trade on the Nasdaq Capital Market and have a pro forma equity value of approximately $421.4 million, with pre-merger InMed shareholders holding about 1.51% of the combined company. The company and merger parties expect to accelerate development timelines and pursue regulatory filings according to the stated milestones.

Led · Series B · Jul 2026

Draig Therapeutics is a clinical-stage biopharma focused on developing highly specific AMPA receptor (AMPAR) and GABAA receptor (GABAAR) modulators aimed at treating neuropsychiatric disorders. Its lead program, DT-101, is a Phase 2 AMPAR positive allosteric modulator (PAM) being evaluated in major depressive disorder in a global monotherapy study and a U.S. adjunct study. The company states DT-101 has shown encouraging safety, tolerability and target engagement with a pulsatile pharmacokinetic profile. Draig was co-founded by Cardiff University and SV Health Investors and is backed by venture investors including Access Biotechnology, Canaan Partners, SR One, Sanofi Ventures and Schroders Capital. Following the oversubscribed $65 million Series B, the company plans to use proceeds to accelerate clinical development across its pipeline and advance additional candidates toward the clinic.

Participated · Series B · Jun 2026

Oblenio Bio is advancing LBL-051, a tri-specific T-cell engager that unites BCMA, CD19 and CD3 and is specifically engineered for autoimmune patients. Preclinical data presented at EULAR 2026 showed complete depletion of peripheral and tissue B cells and plasma cells with step-up dosing, emergence of immature non-memory B cells upon recovery, dose-dependent decreases in peripheral immunoglobulins, and no observed cytokine release syndrome in non-human primates. The company is moving rapidly toward clinical development and plans to initiate a first-in-human proof-of-concept study this year. Oblenio holds an exclusive option from Leads Biolabs for a global license to develop, manufacture, and commercialize LBL-051. Its leadership team includes CEO Samantha Truex, and the board will include representatives from Pfizer Ventures, Deep Track Capital, and Aditum Bio following the Series B. Oblenio is based in Cambridge, Mass., and has just completed a $62 million Series B to fund its clinical program.

Participated · Series C · Jun 2026

Triveni Bio develops antibody-based therapeutics using a genetics-informed, precision medicine approach to address immunological and inflammatory disorders. Its lead program, TRIV-509, is a half-life extended monoclonal antibody targeting kallikreins 5 and 7 and is in an ongoing Phase 2 proof-of-concept trial with data expected at the end of 2026. TRIV-573 is a half-life extended, second-generation bispecific that combines KLK5/7 inhibition with a potent anti–IL-13 mechanism; first-in-human studies have been initiated and a Phase 2 trial in atopic dermatitis is planned later this year. The company intends to use recent Series C proceeds to expand TRIV-573 clinical development and to explore related barrier disorder indications. Triveni is led by CEO Vishal Patel, Ph.D., and recently added Evan Rachlin, M.D., to its board following the financing.

Participated · Series A · May 2026

cAMPfield Therapeutics is a newly formed biotechnology company backed by Mountainfield Venture Partners and other life-science investors to advance licensed development-stage therapeutic candidates. Its CEO, Bill Gerhart, has more than two decades of experience in pulmonary, fibrosis, and inflammatory diseases and a track record of leading biotech exits. Other senior leaders include CTO Patricia Turney and global head of regulatory affairs Rita Shah. Public filings and reporting link cAMPfield to vTv Therapeutics' HPP737, a PDE4 inhibitor that has been studied in China for psoriasis, COPD, atopic dermatitis, and idiopathic pulmonary fibrosis, including an ongoing Phase 3 psoriasis trial there. The company's explicit pipeline needs are not detailed in the coverage, nor are financial metrics beyond the $180 million Series A. cAMPfield appears positioned to progress licensed candidates through clinical development with capital from its recent financing.